# US 2025/0154207 A1 · Peptides for dissolving protein aggregates and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154207 A1
- Document ID: US20250154207A1
- Status: Published application
- Kind: A1
- Application number: 18/838,613
- Filed: 2023-02-17
- Published: 2025-05-15
- Earliest claimed: 2022-02-17
- Assignees: Rejukon Biopharm Inc.
- Applicants: Rejukon Biopharm Inc.
- Inventors: Chenchen WANG
- Web page: https://patentgrep.com/patent/US20250154207A1

## CPC

- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/245: Escherichia (G)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/86: Viral vectors
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides a method of generating a peptide capable of dissolving protein aggregates. Also provided is a method of treating a neurodegeneration disease using such peptide.

## Claims

### Claim 1

A method of generating a peptide capable of dissolving a protein aggregate, the method comprising:
identifying a naturally occurred protein having a charged amphipathic (Champ) region of 40 to 100 amino acid residues, wherein
(a) at least 30 percent of the amino acid residues in the Champ region are charged amino acid residues selected from Asp, Glu, Arg and Lys, wherein at least 80 percent of the charged amino acid residues are in the N-terminus or C-terminus of the Champ region,
(b) 14 percent to 26 percent of the amino acid residues in the Champ region are hydrophobic amino acid residues selected from Phe, Cys, Leu, Val and Ile, and
(c) at least 10 percent of the amino acid residues in the Champ region are polar amino acid residues selected from Ser, Asn, Thr, Gln, Tyr, Cys and His, and
generating a peptide consisting of the Champ region.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
contacting the peptide with a protein aggregate; and
determining that the peptide dissolves the protein aggregate.

### Claim 3 (depends on 1)

The method of claim 1, further comprising mutating any one of the charged amino acid residues in the peptide to a different a charged amino acid residue.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide is selected from SEQ ID NO: 1-15.

### Claim 5 (depends on 1, 2, 3, 4)

A peptide generated according to the method of any one of claims 1-4.

### Claim 6 (depends on 5)

A polynucleotide encoding the peptide of claim 5.

### Claim 7 (depends on 6)

The polynucleotide of claim 6, which is a DNA or an RNA.

### Claim 8 (depends on 6, 7)

A vector comprising the polynucleotide of claim 6 or 7.

### Claim 9 (depends on 8)

The vector of claim 8, which is a virus vector.

### Claim 10 (depends on 9)

The vector of claim 9, which is an AAV vector.

### Claim 11 (depends on 6, 7)

A recombinant virus comprising the polynucleotide of claim 6 or 7.

### Claim 12 (depends on 11)

The recombinant virus of claim 11, which is an AAV.

### Claim 13 (depends on 6, 7)

A host cell comprising the polynucleotide of claim 6 or 7.

### Claim 14 (depends on 5, 6, 7, 8, 9, 10, 11, 12, 13)

A pharmaceutical composition comprising (1) the peptide of claim 5, the polynucleotide of claim 6 or 7, the vector of any one of claims 8-10, the recombinant virus of claim 11 or 12, or the host cell of claim 13, and (2) a pharmaceutically acceptable carrier.

### Claim 15 (depends on 5)

A method for dissolving a protein aggregate in a cell, the method comprising introducing into the cell the peptide of claim 5.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cell is a neuronal cell.

### Claim 17 (depends on 15)

The method of claim 15, wherein the cell is in vitro or in vivo.

### Claim 18 (depends on 14)

A method for treating a neurodegeneration disease in a subject in need thereof, the method comprising administering to the subject a therapeutic effective amount of the pharmaceutical composition of claim 14.

### Claim 19 (depends on 18)

The method of claim 18, wherein the neurodegeneration disease is selected from frontotemporal dementia, amyotrophic lateral sclerosis, cortical basal ganglia degeneration, Lewy body dementia, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body Myositis, Parkinson's disease, argyrophilic granular disease, Alzheimer's disease, Parsons/dementia complex in the Kii Peninsula, progressive supranuclear palsy, and Pick's disease.

### Claim 20 (depends on 19)

The method claim 19, wherein the pharmaceutical composition is administered to the central nervous system.

### Claim 21 (depends on 20)

The method claim 20, wherein the pharmaceutical composition is administered via spinal cord injection, intrathecal injection, intracerebroventricular injection, intracerebral injection, or intra-hippocampal injection.
